Squarepoint Ops LLC Has $1.13 Million Position in Exelixis, Inc. $EXEL

Squarepoint Ops LLC cut its holdings in shares of Exelixis, Inc. (NASDAQ:EXEL) by 49.5% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 25,613 shares of the biotechnology company’s stock after selling 25,087 shares during the quarter. Squarepoint Ops LLC’s holdings in Exelixis were worth $1,129,000 at the end of the most recent reporting period.

Other hedge funds also recently modified their holdings of the company. AQR Capital Management LLC raised its holdings in Exelixis by 73.8% during the first quarter. AQR Capital Management LLC now owns 6,893,889 shares of the biotechnology company’s stock worth $250,869,000 after acquiring an additional 2,926,884 shares in the last quarter. Norges Bank acquired a new position in shares of Exelixis during the 2nd quarter worth approximately $122,099,000. Qube Research & Technologies Ltd raised its stake in shares of Exelixis by 120.5% during the 2nd quarter. Qube Research & Technologies Ltd now owns 3,047,222 shares of the biotechnology company’s stock worth $134,306,000 after purchasing an additional 1,665,110 shares in the last quarter. Arrowstreet Capital Limited Partnership raised its stake in shares of Exelixis by 42.9% during the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 5,262,643 shares of the biotechnology company’s stock worth $231,951,000 after purchasing an additional 1,580,567 shares in the last quarter. Finally, Prudential Financial Inc. boosted its holdings in shares of Exelixis by 776.8% in the 2nd quarter. Prudential Financial Inc. now owns 1,468,865 shares of the biotechnology company’s stock valued at $64,740,000 after buying an additional 1,301,330 shares during the last quarter. Institutional investors own 85.27% of the company’s stock.

Insider Transactions at Exelixis

In other Exelixis news, EVP Patrick J. Haley sold 34,187 shares of Exelixis stock in a transaction dated Thursday, November 20th. The shares were sold at an average price of $41.88, for a total value of $1,431,751.56. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Dana Aftab sold 48,383 shares of the stock in a transaction that occurred on Tuesday, November 11th. The stock was sold at an average price of $42.50, for a total transaction of $2,056,277.50. Following the transaction, the executive vice president owned 664,778 shares in the company, valued at approximately $28,253,065. The trade was a 6.78% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 245,235 shares of company stock worth $10,490,600 over the last quarter. 2.85% of the stock is currently owned by corporate insiders.

Exelixis Stock Up 4.1%

Shares of EXEL stock opened at $44.30 on Monday. Exelixis, Inc. has a 12-month low of $31.90 and a 12-month high of $49.62. The company has a market capitalization of $11.88 billion, a PE ratio of 18.69, a price-to-earnings-growth ratio of 0.80 and a beta of 0.40. The firm has a 50 day moving average price of $41.10 and a two-hundred day moving average price of $40.79.

Exelixis (NASDAQ:EXEL) last posted its earnings results on Tuesday, November 4th. The biotechnology company reported $0.78 EPS for the quarter, beating the consensus estimate of $0.68 by $0.10. The company had revenue of $597.76 million for the quarter, compared to the consensus estimate of $590.04 million. Exelixis had a return on equity of 31.06% and a net margin of 29.63%.The firm’s revenue for the quarter was up 10.8% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.47 earnings per share. As a group, research analysts expect that Exelixis, Inc. will post 2.04 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts have issued reports on the stock. Wolfe Research began coverage on shares of Exelixis in a research report on Tuesday, November 18th. They set a “peer perform” rating on the stock. Wall Street Zen upgraded shares of Exelixis from a “buy” rating to a “strong-buy” rating in a research note on Sunday, December 14th. Wells Fargo & Company dropped their target price on shares of Exelixis from $36.00 to $30.00 and set an “equal weight” rating on the stock in a report on Tuesday, October 21st. Zacks Research cut Exelixis from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 26th. Finally, The Goldman Sachs Group assumed coverage on Exelixis in a research report on Wednesday, September 17th. They set a “buy” rating and a $47.00 price target on the stock. One research analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and eleven have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $45.74.

Exelixis Profile

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.